Incyte Corp (NASDAQ:INCY)

graph

Despite Target Cuts, Analysts Stick With Incyte for Big Upside

Incyte Corp. (NASDAQ: INCY) took it on the chin this past week following the announcement that its Phase 2 trial of ruxolitinib would be stopped. This was detrimental to the ...
Read Full Story »
buy sell

Top Analyst Upgrades and Downgrades: Boeing, eBay, Facebook, Incyte, Kinder Morgan, PayPal, Qualcomm, US Steel and More

Stocks were indicated slightly higher on Thursday after a dovish Federal Reserve decision on rates did not keep selling pressure away on Wednesday. Investors may have seen every rally of ...
Read Full Story »
biotech word cloud

Despite Market and Sector Risks, Why Credit Suisse Now Loves Top Biotechs

Credit Suisse sees solid fundamentals, despite a harsh market landscape, for large-cap biotech firms. There is a challenging macro setup, but headwinds combined with a relatively attractive valuation could carry ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: AMD, Amazon, Celgene, Comerica, Fortinet, Gilead, Lennar, Netflix, Voya, Wayfair and Many More

Stocks were getting bruised on Wednesday with overseas pressure and oil sending Dow (-250) and S&P (-29) futures down yet again. Investors have to be thinking that 2016 is becoming ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: Bluebird Bio, Check Point, Comcast, Eli Lilly, Hyatt, Lockheed Martin, Rite Aid and Many More

Stocks were pounded lower yet again on Wednesday, but this time on fears of a North Korean hydrogen bomb test. The stock market is off to a rocky start in ...
Read Full Story »
biotech word cloud

Hot Biotech Stocks Highlight Jefferies Top Growth Stocks to Buy This Week

Despite a very difficult week for investors, more data came in to support the huge jobs number at the beginning of the month. The NFIB Small Business Optimism Index held ...
Read Full Story »
Test tubes

Big Biotech Is Cheap With Strong Cash Flows: 3 to Buy Before Earnings

The political candidates were at it again during the recent Democratic Party debate. Evil pharmaceutical and biotech companies are charging too much. The fact of the matter is every four ...
Read Full Story »
generic drugs

Why Merrill Lynch Now Favors Large Cap Leaders in Biotech

Since the peak of the biotech index in late July, the industry has dropped a staggering 24% through the end of the third quarter, versus the 10% drop in the ...
Read Full Story »
buy sell

Jefferies Starts Coverage on Biotechs: 3 Top Stocks to Buy Now

Despite the tremendous run the biotech sector has had over the past five years, many of the top stocks, especially the large cap leaders, trade at multiples that mimic low-growth ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Exxon, Home Depot, Lululemon, 3M, Vodafone, Mondelez, Chevron and More

Stocks were marginally lower on Monday to kick off the week, after the prior week was in the red. The one trend that is nearly four years old is that ...
Read Full Story »
biotech

Why These 4 Biotech Stocks Could Be the Next Buyout Targets

There should be no surprise to biotech investors that the mergers and acquisition (M&A) market and chatter are heating up. The huge buy of Synageva Biopharma Corp. (NASDAQ: GEVA) by ...
Read Full Story »
Pills

The Next 3 Likely Biotech Buyout Candidates

One good way for a company to increase sales and move past simple organic growth is to make an acquisition, and that is just what AbbVie Inc. (NYSE: ABBV) did ...
Read Full Story »
Perfume image

Insider Selling Remains Choppy as Stock Market Grinds Higher

In a trend that seems somewhat locked into place, like the horrible winter weather in the Northeast, insiders continue to sell stock, though as we have seen most of this ...
Read Full Story »
DNA

Has Agenus Run Too Much?

Agenus Inc. (NASDAQ: AGEN), in conjunction with Incyte Corp. (NASDAQ: INCY), announced a global license for the development and commercialization of Agenus’s proprietary Retrocyte Display antibody discovery platform. As a ...
Read Full Story »
fda_logo

5 Critical Biotech Drug Dates and Events for December

At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks. These events refer to reviews and decisions by the U.S. Food ...
Read Full Story »